Loading...
•
Jun 30, 2022
Innoviva Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022 and highlighted recent company progress.
Key Takeaways
Innoviva's core royalty business continued to deliver strong revenues, and the company meaningfully advanced its strategy via key strategic and opportunistic transactions, including the acquisition of Entasis and the announced acquisition of La Jolla.
Core royalty business delivered strong revenues.
Acquired Entasis with its strong pipeline anchored by differentiated, promising lead asset SUL-DUR.
Announced acquisition of La Jolla, creating a fully integrated business in the hospital and infectious disease spaces.
Divested stake in Theravance Respiratory Company.
Forward Guidance
Innoviva is well-capitalized and highly cashflow generative company, and is strongly positioned for sustained value creation in the current market environment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...